文章名稱引用次數(shù)

• Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1. irRECIST and iRECIST criteria57
• Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer43
• General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 386 persons across 13 European countries, Canada and the Unites States41
• Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors34
• Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial32
• Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with >= 25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy28
• Deep neural networks are superior to dermatologists in melanoma image classification27
• The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial27
• Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG26
• Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial25